Coagulation Defects

Anesthesiology Clinics of North America

Volumn 24, Issue 3, 2006, Pages 549-578

  Soliman, Doreen E ^a   Broadman, Lynn M ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DESMOPRESSIN; DEXAMETHASONE; ESTROGEN; FIBRIN GLUE; HEPARIN; HIRUDIN; HIRULOG; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RHESUS D ANTIBODY; RISTOCETIN; THROMBIN INHIBITOR; TRANEXAMIC ACID; UNINDEXED DRUG; VALPROIC ACID; VON WILLEBRAND FACTOR; WARFARIN;

ACTIVATED PROTEIN C RESISTANCE; AFIBRINOGENEMIA; ANALYZER; ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; BLEEDING TIME; BLOOD ANALYSIS; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 10 DEFICIENCY; BLOOD CLOTTING FACTOR 11 DEFICIENCY; BLOOD CLOTTING FACTOR 5 DEFICIENCY; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BONE MARROW TRANSPLANTATION; CLINICAL FEATURE; CONGENITAL HYPERCOAGULABLE SYNDROME; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DISEASE TRANSMISSION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG COST; DRUG INDICATION; DYSFIBRINOGENEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGICAL DATA; FLUID INTAKE; FLUSHING; GENE MUTATION; GENE THERAPY; GENETIC RISK; HEADACHE; HEMOPHILIA A; HEMOPHILIA B; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERCOAGULABILITY; HYPONATREMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INTERMETHOD COMPARISON; LABORATORY TEST; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; LONG TERM CARE; MENINGOCOCCEMIA; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PHENOTYPE; PLASMAPHERESIS; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; PROTHROMBIN DEFICIENCY; PROTHROMBIN TIME; REGIONAL ANESTHESIA; RELIABILITY; REPRODUCIBILITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEIZURE; SIDE EFFECT; SPLENECTOMY; TACHYCARDIA; THROMBIN TIME; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE ANOMALY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOELASTOGRAPHY; THROMBOSIS; TREATMENT OUTCOME; TREATMENT PLANNING; VITAMIN K DEFICIENCY; VON WILLEBRAND DISEASE;

ANESTHESIA; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; BLOOD LOSS, SURGICAL; HUMANS; PERIOPERATIVE CARE; SURGICAL PROCEDURES, OPERATIVE;

EID: 33748787418     PISSN: 08898537     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atc.2006.05.009     Document Type: Review

References (150)

1. Bombeli T., and Spahn D.R. Updates in perioperative coagulation: physiology and management of thromboembolism and haemorrhage. Br J Anaesth 93 (2004) 275-287
2. Spiess B.D. Coagulation monitoring in the perioperative period. Int Anesthesiol Clin 42 (2004) 55-71
3. Vapaatalo H., and Mervaala E. Clinically important factors influencing endothelial function. Med Sci Monit 7 5 (2001) 1075-1085 [Review.]
4. Ramasamy I. Inherited bleeding disorders: disorders of platelet adhesion and aggregation. Crit Rev Oncol Hematol 49 1 (2004) 1-35
5. Price G.C., Thompson S.A., and Kam P.C. Tissue factor and tissue factor pathway inhibitor. Anaesthesia 59 5 (2004) 483-492
6. Bates S.M., and Weitz J.I. Coagulation assays. Circulation 112 (2005) 53-60
7. Smith S.A., and Morrissey J.H. Properties of recombinant human thromboplastin that determine the International Sensitivity index (ISI). J Thromb Haemost 2 (2004) 1610-1616
8. Johnson C.M., Mureebe L., and Silver D. Hypercoagulable states: a review. Vasc Endovascular Surg 39 (2005) 123-133
9. Lewis K.D., and Hassell K.L. Hypercoagulability: proper workup following deep vein thrombosis. Primary Care Case Reviews 6 (2003) 57-66
10. Roberts H.R., Stinchcombe T.E., and Gabriel D.A. The dysfibrinogenemias. Br J Haematol 114 (2001) 249-257
11. Sorensen B., Johansen P., Christiansen K., et al. Whole blood coagulation thromboelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 1 (2003) 551-558
12. Sorensen B., and Ingerslev J. Tailoring haemostatic treatment to patient requirements-an update on monitoring haemostatic response using thrombelastography. Haemophilia 11 Suppl 1 (2005) 1-6
13. Rodgers R.P., and Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 16 (1990) 1-16
14. Harrison P. The role of PFA-100 testing in the investigation and management of hemostatic defects in children and adults. Br J Haematol 130 (2005) 3-10
15. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 138 (2001) 152-163
16. Dyszkiewicz-Korpanty A., Quinton R., Yassine J., et al. The effect of a pneumatic tube transport system on PFA-100 trade mark closure time and whole blood platelet aggregation. J Thromb Haemost 2 (2004) 354-356
17. Kundu S.K., Heilmann E.J., Sio R., et al. Description of an in vitro platelet function analyzer-PFA-100. Semin Thromb Hemost 21 (1995) 106-112
18. Kerenyi A., Schlammadinger A., Ajzner E., et al. Comparison of PFA-100 closure time and template bleeding time of patients with inherited disorders causing defective platelet function. Thromb Res 96 (1999) 487-492
19. Sadler J.E., Mannucci P.M., Berntorp E., et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 84 (2000) 160-174
20. Schneppenheim R. The evolving classification of von Willebrand disease. Blood Coagul Fibrinolysis 16 Suppl 1 (2005) S3-S10
21. Dahlback B. Blood coagulation and its regulation by coagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. J Intern Med 257 (2005) 209-223
22. Lee J.W. Von Willebrand disease, hemophilia A and B, and other factor deficiencies. Int Anesthesiol Clin 42 (2004) 59-76
23. Zaverio M., and Ruggeri M.D. von Willebrand factor. Curr Opin Hematol 10 (2003) 142-149
24. Mancuso D.J., Tuley E.A., Westfield L.A., et al. Structure of the gene for human von Willebrand factor. J Biol Chem 264 33 (1989) 19514-19527
25. Ginsburg D., Handin R.I., Bonthron D.T., et al. Willebrand factor (vWF): Isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 228 (1985) 1401-1406
26. Ruggeri Z.M. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Pract Res Clin Haematol 14 (2001) 257-279
27. Holmberg L., and Nilsson I.M. Von Willebrand disease. Clin Haematol 14 (1985) 461-488
28. Nichols W.C., and von Ginsburg D. Willebrand disease. Medicine (Baltimore) 76 (1997) 1-20
29. Federici A.B., Castaman G., Mannucci P.M., and for the Italian Association of Hemophilia Centers (AICE). Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 8 (2002) 607-621
30. Sadler J.E. The subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society of Thrombosis and Hemostasis. A revised classification of von Willebrand disease. Thromb Haemost 71 (1994) 520-525
31. Kenny S., and Cumming A.M. The molecular biology of von Willebrand disease. Clin Lab Haematol 23 (2001) 209-230
32. Zimmerman T.S., Ratnoff O.D., and Powell A.E. Immunologic differentiation of classic hemophelia (factor 8 deficiency) and von Willebrand's disease, with observations on combined deficiencies of antihemophilic factor proaccelerin (factor v) and on an acquired circulating anticoagulant against antihemophilic factor. J Clin Invest 50 (1971) 244-254
33. Foster P.A., Fulcher C.A., Marti T., et al. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem 262 (1987) 8443-8446
34. Rodeghiero F. Congenital von Willebrand disease type 1 definition, phenotypes, clinical and laboratory assessment. Best Pract Res Clin Haematol 14 (2001) 321-335
35. Budde U., Drewke E., Mainusch K., et al. Laboratory diagnosis of congenital von Willebrand disease. Semin Thromb Hemost 28 (2002) 173-190
36. Michiels J.J., Budde U., van der Planken M., et al. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Haematol 14 (2001) 401-436
37. Favaloro E.J., Bonar R., Kershaw G., et al. Laboratory diagnosis of von Willebrand disorder: use of multiple functional assays reduces diagnostic error rates. Lab Hematol 11 (2005) 91-97
38. Posan E., McBane R.D., Grill D.E., et al. Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice. Thromb Haemost 90 (2003) 483-490
39. Favaloro E.J. Utility of the PFA-100 for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations. Haemophilia 7 (2001) 170-179
40. Preston F.E. Assays for von Willebrand factor functional activity: a UK NEQAS survey. National External Quality Assessment Scheme. Thromb Haemost 80 (1998) 863
41. Michiels J.J., Gadisseur A., Budde U., et al. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences. Semin Thromb Hemost 31 (2005) 577-601
42. Slaughter T.F., Parker J.K., and Greenberg C.S. A rapid method for the diagnosis of von Willebrand's disease subtypes by the clinical laboratory. Arch Pathol Lab Med 119 (1995) 148-152
43. Neugebauer B.M., Goy C., Budek I., et al. Comparison of two von Willebrand factor collagen-binding assays with different binding affinities for low, medium, and high multimers of von Willebrand factor. Semin Thromb Hemost 28 (2002) 139-148
44. Lopez-Fernandez M.F., Lopez-Berges C., Martin-Bernal J.A., et al. Type IIB von Willebrand's disease associated with a complex thrombocytopenic thrombocytopathy. Am J Hematol 27 (1988) 291-298
45. Nolan B., White B., Smith J., et al. OP.Desmopressin: therapeutic limitations in children and adults with inherited coagulation disorders. Br J Haematol 109 (2000) 865-869
46. Mannucci P.M. How I treat patients with von Willebrand disease. Blood 97 (2001) 1915-1919
47. Mannucci P.M., Canciani M.T., Rota L., et al. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand disease. Br J Haematol 47 (1981) 283-293
48. Mannucci P.M. Desmopressin (DDAVP) for treatment of disorders of hemostasis. Prog Hemost Thromb 8 (1986) 19-45
49. Mannucci P.M., Bettega D., and Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 82 (1992) 87-93
50. Lethagen S. Desmopressin in mild hemophilia A: indications, limitations, efficacy, and safety. Semin Thromb Hemost 29 (2003) 101-106
51. Lusher J.M. Response to 1-deamino-8-D-arginine vasopressin in von Willebrand disease. Haemostasis 24 (1994) 276-284
52. Das P., Carcao M., and Hitzler J. DDAVP-Induced hyponatremia in young children. J Pediatr Hematol Oncol 27 (2005) 330-332
53. Dunn A.L., Powers J.R., Ribeiro M.J., et al. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients. Haemophilia 6 (2000) 11-14
54. Thumfart J., Roehr C.C., Kapelari K., et al. Desmopressin associated symptomatic hyponatremic hypervolemia in children. Are there predictive factors?. J Urol 174 (2005) 294-298 [discussion: 298]
55. Allen G.C., Armfield D.R., Bontempo F.A., et al. Adenotonsillectomy in children with von Willebrand disease. Arch Otolaryngol Head Neck Surg 125 (1999) 547-551
56. Delfanian K., and Zawada Jr. E.T. DDAVP-associated hyponatremia. S D J Med 54 (2001) 255-256
57. Federici A.B., Baudo F., Caracciolo C., et al. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study. Haemophilia 8 (2002) 761-767
58. Batlle J., Noya M.S., Giangrande P., et al. Advances in the therapy of von Willebrand disease. Haemophilia 8 (2002) 301-307
59. Josephson C.D., and Abshire T.C. Clinical uses of plasma and plasma fractions: plasma-derived products for hemophilias A and B, and for von Willebrand disease. Best Pract Res Clin Haematol 19 (2006) 35-49
60. Hambleton J. Advances in the treatment of von Willebrand disease. Semin Hematol 38 Suppl 9 (2001) 7-10
61. Federici A.B. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys. Blood Coagul Fibrinolysis 16 Suppl 1 (2005) S17-S21
62. Saulnier J., Marey A., Horellou M.H., et al. Evaluation of desmopressin for dental extractions in patients with hemostatic disorders. Oral Surg Oral Med Oral Pathol 77 (1994) 6-12
63. Franchini M., Rossetti G., Tagliaferri A., et al. Dental procedures in adult patients with hereditary bleeding disorders: 10 years experience in three Italian hemophilia centers. Haemophilia 11 (2005) 504-509
64. Federici A.B., Sacco R., Stabile F., et al. Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases. Haemophilia 6 (2000) 71-77
65. Kubisz P., and Stasko J. Recombinant activated factor VII in patients at high risk of bleeding. Hematology (Am Soc Hematol Educ Program) 9 (2004) 317-332
66. Majumdar G., Phillips J.K., Lavallee H., et al. Acquired haemophilia in association with type III von Willebrand's disease: successful treatment with high purity von Willebrand's factor and recombinant factor VIIa. Blood Coagul Fibrinolysis 4 (1993) 1035-1037
67. Grossmann R.E., Geisen U., Schwender S., et al. Continuous infusion of recombinant factor VIIa (NovoSeven) in the treatment of a patient with type III von Willebrand's disease and alloantibodies against von Willebrand factor. Thromb Haemost 83 (2000) 633-634
68. Ciavarella N., Schiavoni M., Valenzano E., et al. Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor. Haemostasis 26 Suppl 1 (1996) 150-154
69. Bolton-Maggs P.H., and Pasi K.J. Haemophilias A and B. Lancet 361 (2003) 1801-1809
70. Xuefeng W., Yuanfang L., Zhiguang L., et al. Carrier detection and prenatal diagnosis of hemophilia A. Clin Chem Lab Med 39 12 (2001) 1204-1208
71. Soucie J.M., Evatt B., and Jackson D. Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol 59 (1998) 288-294
72. Venkateswaran L., Wilimas J.A., Jones D.J., et al. Mild hemophilia in children: prevalence, complications, and treatment. J Pediatr Hematol Oncol 20 (1998) 32-35
73. Van de Water N.S., Williams R., Nelson J., et al. Factor VIII gene inversions in severe hemophilia A patients. Pathology 27 (1995) 83-85
74. Graw J., and Brackmann H.H. Hemophilia A: from mutation analysis to new therapies. Nat Rev Genet 6 (2005) 488-501
75. White II G.C., Rosendaal F., Aledort L.M., et al. Factor VIII and Factor IX Subcommittee. Definitions in hemophilia, recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Thromb Haemost 85 (2001) 560
76. MacLean P.E., Fijnvandraat K., Beijlevelt M., et al. The impact of unaware carriership on the clinical presentation of haemophilia. Haemophilia 10 (2004) 560-564
77. Keeney S., Mitchell M., and Goodeve A. The molecular analysis of haemophilia A: a guideline from the UK haemophilia centre doctors' organization haemophilia genetics laboratory network. Haemophilia 11 (2005) 387-397
78. Heyworth B.E., Su E.P., Figgie M.P., et al. Orthopedic management of hemophilia. Am J Orthop 34 10 (2005) 479-486
79. Luck J.V., and Silva M. Hemophiliac arthropathy. J Am Acad Orthop Surg 12 (2004) 234-245
80. Albanese A., Tuttolomondo A., Anile C., et al. Spontaneous chronic subdural hematomas in young adults with a deficiency in coagulation factor XIII. Report of three cases. J Neurosurg 102 (2005) 1130-1132
81. Thomas A.E. The bleeding child; is it NAI?. Arch Dis Child 89 12 (2004) 1163-1167
82. Kitchens C.S. To bleed or not to bleed? Is that the question for the PTT?. J Thromb Haemost 3 (2005) 2607-2611
83. Pool J.G., and Shannon A.E. Production of high-potency concentrates of antihemophilic globulin in a closed-bag system. N Engl J Med 273 (1965) 1443-1447
84. Chorba T.L., Holman R.C., Strine T.W., et al. Changes in longevity and causes of death among persons with hemophilia A. Am J Hematol 45 (1994) 112-121
85. Yee T.T., and Lee C.A. Transfusion-transmitted infection in hemophilia in developing countries. Semin Thromb Hemost 31 (2005) 527-537
86. Franchini M. Hepatitis C in haemophiliacs. Thromb Haemost 92 6 (2004) 1259-1268
87. Jones P.K., and Ratnoff O.D. The changing prognosis of classic hemophilia (factor VIII "deficiency"). Ann Intern Med 114 (1991) 641-648
88. Association of Hemophilia Clinic Directors of Canada. Hemophilia and von Willebrand's disease: management. CMAJ 153 (1995) 147-157
89. Zavoico G.B. Advances in factor replacement therapy for hemophilia A and B and the promise of gene therapy. Drug Mark Dev 12 (2001) 71-78
90. Pipe S.W. The promise and challenges of bioengineered recombinant clotting factors. J Thromb Haemost 3 (2005) 1692-1701
91. Schlesinger K.W., and Ragni M.V. Safety of the new generation recombinant factor concentrates. Expert Opin Drug Saf 1 (2002) 213-223
92. Klinge J., Ananyeva N.M., Hauser C.A., et al. Hemophilia A-from basic science to clinical practice. Semin Thromb Hemost 28 (2002) 309-322
93. Josephson C.D., and Abshire T. The new albumin-free recombinant factor VIII concentrates for treatment of hemophilia: do they represent an actual incremental improvement?. Clin Adv Hematol Oncol 2 (2004) 441-446
94. Dingli D., Gastineau D.A., Gilchrist G.S., et al. Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates. Haemophilia 8 (2002) 629-634
95. Bohn R.L., Aledort L.M., Putnam K.G., et al. The economic impact of factor VIII inhibitors in patients with haemophilia. Haemophilia 10 (2004) 63-68
96. Globe D.R., Curtis R.G., Koerper M.A., and HUGS. Steering Committee. Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS). Haemophilia 10 Suppl 1 (2004) 63-70
97. Shord S.S., and Lindley C.M. Coagulation products and their uses. Am J Health Syst Pharm 57 (2000) 1403-1417 [quiz: 1418-20]
98. DiMichele D., and Neufeld E.J. Hemophilia. A new approach to an old disease. Hematol Oncol Clin North Am 12 (1998) 1315-1344
99. Lofqvist T., Nilsson I.M., Berntorp E., et al. Haemophilia prophylaxis in young patients-a long-term follow-up. J Intern Med 241 (1997) 395-400
100. Kreuz W., Ettingshausen C.E., Zyschka A., et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Hemost 28 (2002) 285-290
101. Brettler D.B. Inhibitors in congenital haemophilia. Baillieres Clin Haematol 9 (1996) 319-329
102. Vlot A.J., Wittebol S., Strengers P.F., et al. Factor VIII inhibitor in a patient with mild haemophilia A and an Asn618→Ser mutation responsive to immune tolerance induction and cyclophosphamide. Br J Haematol 117 (2002) 136-140
103. Bechtloff S., Tran-My B., Haubelt H., et al. A prospective trial on the safety of long-term intensive plasmapheresis in donors. Vox Sang 88 (2005) 189-195
104. Freedman J., and Garvey M.B. Immunoadsorption of factor VIII inhibitors. Curr Opin Hematol 11 (2004) 327-333
105. von Depka M. Managing acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safety. Haemophilia 11 Suppl 1 (2005) 18-23
106. Knight C. Health economics of treating haemophilia A with inhibitors. Haemophilia 11 Suppl 1 (2005) 11-17
107. Hedner U., and Erhardtsen E. Potential role of recombinant factor VIIa as a hemostatic agent. Clin Adv Hematol Oncol 1 (2003) 112-119
108. Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia 5 (1999) 253-259
109. Gerotziafas G.T., Chakroun T., Depasse F., et al. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. Thromb Haemost 91 5 (2004) 977-985
110. Veldman A., Hoffman M., and Ehrenforth S. New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa. Curr Med Chem 10 (2003) 797-811
111. Aledort L.M. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2 10 (2004) 1700-1708
112. Kessler C.M. New perspectives in hemophilia treatment. Hematology (Am Soc Hematol Educ Program) 1 (2005) 429-435
113. Pipe S.W. Coagulation factors with improved properties for hemophilia gene therapy. Semin Thromb Hemost 30 (2004) 227-237
114. Bauer K.A. Hypercoagulable states. In: Hoffman B., Benz Jr. E.J., Shattil S.J., et al. (Eds). Hematology: basic principles and practice. 4th edition (2005), Elsevier Churchill Livingstone, Philadelphia 2197-2224
115. Srinivasan A.F., Rice L., Bartholomew J.R., et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 164 (2004) 66-70
116. Gomez K., McVey J.H., and Tuddenham E. Inhibition of coagulation by macromolecular complexes. Haematologica 90 (2005) 1570-1576
117. Espana F., Medina P., Navarro S., et al. The multifunctional protein C system. Curr Med Chem Cardiovasc Hematol Agents 3 (2005) 119-131
118. Molino D., De Lucia D., Marotta R., et al. In uremia, plasma levels of anti-protein C and anti-protein S antibodies are associated with thrombosis. Kidney Int 68 (2005) 1223-1229
119. Zheng Y.Z., Sakata T., Matsusue T., et al. Six missense mutations associated with type I and type II protein C deficiency and implications obtained from molecular modelling. Blood Coagul Fibrinolysis 5 (1994) 687-696
120. Kearon C., Crowther M., and Hirsh J. Management of patients with hereditary hypercoagulable disorders. Annu Rev Med 51 (2000) 169-185
121. Brouwer J.L., Veeger N.J., van der Schaaf W., et al. Difference in absolute risk of venous and arterial thrombosis between familial protein S deficiency type I and type III. Results from a family cohort study to assess the clinical impact of a laboratory test-based classification. Br J Haematol 128 5 (2005) 703-710
122. League S., and Hooper W.C. Molecular diagnostics of inherited thrombosis. Clin Lab Sci 18 4 (2005) 271-279
123. Pablos J.L., Caliz R.A., Carreira P.E., et al. Risk of thrombosis in patients with antiphospholipid antibodies and factor V Leiden mutation. J Rheumatol 26 (1999) 588-590
124. Kenet G., Sadetzki S., Murad H., et al. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke 31 6 (2000) 1283-1288
125. Brugge J.M., Simioni P., Bernardi F., et al. Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation. J Thromb Haemost 3 12 (2005) 2695-2702
126. Favaloro E.J. Diagnostic issues in thrombophilia: a laboratory scientist's view. Semin Thromb Hemost 31 1 (2005) 11-16
127. Bauer K.A. Role of thrombophilia in deciding on the duration of anticoagulation. Semin Thromb Hemost 30 6 (2004) 633-637
128. Tripodi A. Issues concerning the laboratory investigation of inherited thrombophilia. Mol Diagn 9 4 (2005) 181-186
129. Lewis K.D., and Hassell K.I. Hypercoagulability: proper workup following deep vein thrombosis. Primary Care Case Reviews 6 (2003) 57-66
130. Caprini J.A., Glase C.J., Anderson C.B., et al. Laboratory markers in the diagnosis of venous thromboembolism. Circulation 109 Suppl 1 (2004) I4-I8
131. Kearon C. Duration of anticoagulation for venous thromboembolism. J Thromb Thrombolysis 12 (2001) 59-65
132. Hayward C.P.M. Inherited platelet disorders. Curr Opin Hematol 10 (2003) 362-368
133. Reid T.J., Rentas F.J., and Ketchum L.H. Platelet substitutes in the management of thrombocytopenia. Curr Hematol Rep 2 2 (2003) 165-170
134. Poon M.C., and d'Oiron R. Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group. Blood Coagul Fibrinolysis 11 Suppl 1 (2000) S55-S68
135. Johnson A., Goodall A.H., Downie C.J., et al. Bone marrow transplantation for Glanzmann's thrombasthenia. Bone Marrow Transplant 14 1 (1994) 147-150
136. Cines D.B., and Bussel J.B. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 106 7 (2005) 2244-2251
137. Stasi R., Stipa E., Masi M., et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 98 (1995) 436-442
138. Marai I., Zandman-Goddard G., and Shoenfeld Y. The systemic nature of the antiphospholipid syndrome. Scand J Rheumatol 33 6 (2004) 365-372
139. Culic S. Recombinant factor VIIa for refractive haemorrhage in autoimmune idiopathic thrombocytopenic purpura. Br J Haematol 120 (2003) 909-910
140. Cohen Y.C., Djulbegovic B., Shamai-Lubovitz O., et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 160 (2000) 1630-1638
141. George J.N., Kojouri K., Perdue J.J., et al. Management of patients with chronic, refractory idiopathic thrombocytopenic purpura. Semin Hematol 37 3 (2000) 290-298
142. Kojouri K., Vesely S.K., Terrell D.R., et al. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 104 (2004) 2623-2634
143. Calverley D.C., Jones G.W., and Kelton J.G. Splenic radiation for corticosteroid-resistant immune thrombocytopenia. Ann Intern Med 116 (1992) 977-981
144. Waghorn D.J. Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed. J Clin Pathol 54 3 (2001) 214-218
145. Castagnola E., and Fioredda F. Prevention of life-threatening infections due to encapsulated bacteria in children with hyposplenia or asplenia: a brief review of current recommendations for practical purposes. Eur J Haematol 71 5 (2003) 319-326
146. Machesky K.K., and Cushing R.D. Overwhelming postsplenectomy infection in a patient with penicillin-resistant Streptococcus pneumoniae. Arch Fam Med 7 2 (1998) 178-180
147. Hawkinberry D.W., and Broadman L.M. The best approaches toprophylaxis against DVT formation when using a combination of neuraxial anesthesia and the heparins. In: Fleisher L.A. (Ed). Evidenced-based practice of anesthesiology (2004), W.B. Saunders Co., Philadelphia 292-304
148. Broadman L.M. Vitamin K antagonists and spinal axis anesthesia. In: Fleisher L.A. (Ed). Evidenced-based practice of anesthesiology (2004), W.B. Saunders Co., Philadelphia 305-311
149. Broadman L.M. Herbal medications and spinal axis anesthesia. In: Fleisher L.A. (Ed). Evidenced-based practice of anesthesiology (2004), W.B. Saunders Co., Philadelphia 312-313
150. Broadman L.M. Fondaparinux: what is its efficacy and safety in surgical patients?. In: Fleisher L.A. (Ed). Evidenced-based practice of anesthesiology (2004), W.B. Saunders Co., Philadelphia 218-222